Emerald Advisers’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Emerald Advisers’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-300	Closed	-$48K	–	296
2021 Q2	$48K	Sell	300 -25,810	-99%	-$4.14M	﹤0.01%	261
2021 Q1	$4.47M	Sell	26,110 -75,936	-74%	-$15M	0.16%	119
2020 Q4	$22.4M	Sell	102,046 -78,991	-44%	-$17.1M	0.74%	57
2020 Q3	$30.1M	Sell	181,037 -8,206	-4%	-$1.12M	1.24%	22
2020 Q2	$21.6M	Sell	189,243 -37,656	-17%	-$3.65M	0.94%	41
2020 Q1	$17.4M	Buy	226,899 +30,959	+16%	+$2.78M	1.01%	34
2019 Q4	$25.2M	Buy	195,940 +62,330	+47%	+$6.01M	1.07%	29
2019 Q3	$10.4M	Buy	+133,610	New	+$12.5M	0.49%	82

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Emerald Advisers's MRTX Position: Q3 2021 in Review

Emerald Advisers sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2021, closing a stake of 300 shares — an estimated $48K sold.

Emerald Advisers first reported a position in MRTX in Q3 2019 and held it in 8 quarters. The position peaked at $30.1M in Q3 2020. 238 funds tracked by Wall St. Rank hold MRTX as of Q3 2021.

Emerald Advisers reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Emerald Advisers sold 300 Mirati Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $48K.
Emerald Advisers first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2019 and held it in 8 quarters.
Emerald Advisers's Mirati Therapeutics, Inc. Common Stock position peaked at $30.1M in Q3 2020.
238 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Emerald Advisers's 13F filing for Q3 2021, filed 28 Oct 2021.